| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Electra Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $302.9M | Series C | 10/22/2025 | $184.13M | $460.97M | $10.15 | Nextech, EQT Life Sciences, Sanofi, HBM Healthcare Investments, Mubadala Capital, OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital, RA Capital Management | ||||
 | Homeward Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $100.4M | Series B-1 | 8/20/2026 | $30.4M | $398.59M | $12.85 | Undisclosed Investors | ||||
 | Inflammatix | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $186.19M | Series E-2 | 9/12/2024 | $26.2M | $210.31M | $0.15 | Khosla Ventures, Think.Health Ventures, Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare Ventures, RAW Ventures | ||||
 | Kyruus | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $192.53M | Series E | 9/15/2022 | $35.1M | $359.84M | $23.40 | Undisclosed Investors | ||||
 | LeanTaaS | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $214.7M | Series D-2 | 12/10/2020 | $99.66M | $491.79M | $12.72 | Insight Venture Partners, Goldman Sachs | ||||
 | LifeMine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $522.71M | Series E | 8/6/2026 | $150.54M | $469.78M | $0.78 | Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, GV, LoLa Capital Partners, GSK, Invus, ARCH Venture Partners | ||||
 | Mineralys | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $159.18M | Series B | 6/8/2022 | $118M | $267.43M | $0.86 | RA Capital Management, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysis Capital, HealthCor Management, Boulder Ventures, Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments, Adams Street Partners | ||||
 | Moonwalk Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $127.47M | Series B | 9/8/2026 | $70.25M | $242.87M | $6.75 | Alpha Wave Ventures, YK Bioventures, Eli Lilly and Company, ARCH Venture Partners, Khosla Ventures, Future Ventures, Gaorong Ventures | ||||
 | Neuron23 | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $310.11M | Series D | 6/24/2025 | $96.5M | $331.2M | $0.99 | Westlake Village BioPartners, SoftBank, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments, Acorn Bioventures | ||||
 | Nikang Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260.25M | Series C | 5/26/2021 | $200M | $475.12M | $5.74 | Cormorant Asset Management, HBM Healthcare Investments, Octagon Capital Advisors, EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavillion Capital, BlackRock, RA Capital Management, Surveyor Capital, Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors, Logos Capital, CBC Group, RTW Investments, Lilly Asia Ventures, Matrix Partners China, Casdin Capital | ||||
 | Nurx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $90.87M | Series C-1 | 8/11/2020 | $13.31M | $317.71M | $7.32 | Wittington Ventures, Union Square Ventures, Trustbridge Partners, Kleiner Perkins, Comcast Ventures | ||||
 | Secretome Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $57.53M | Series A | 5/27/2026 | $30.5M | $231.7M | $2.29 | RA Capital | ||||
 | Seismic Therapeutic | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $470.32M | Series B | 12/4/2023 | $146.28M | $396.35M | $4.52 | Bessemer Venture Partners, Amgen Ventures, Codon Capital, Alexandria Venture Investments, Gaingels, GC&H, Timothy A. Springer, Lightspeed Venture Partners, Polaris Partners, Boxer Capital, GV, Samsara BioCapital | ||||
 | SynDevRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $52.6M | Series C | 9/30/2024 | $29.35M | $270.23M | $7.23 | Undisclosed Investors | ||||
 | Tetherex Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.65M | Series B | 4/18/2018 | $63.95M | $366.68M | $21.32 | MPM Capital, Philip Jones | ||||
 | THINK Surgical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $249.09M | Series F-1 | 1/27/2026 | $85.98M | $290.29M | $0.28 | Undisclosed Investors | ||||
 | TRIANA Biomedicines | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $230.06M | Series B | 12/3/2025 | $120.06M | $262.22M | $3.04 | Ascenta Capital, Bessemer Venture Partners, YK Bioventures, Regeneron Ventures, Invus, Finchley Healthcare Ventures, RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, Surveyor Capital | ||||
 | Tyra Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $157.64M | Series B | 3/31/2021 | $106.3M | $348.37M | $27.43 | Nextech Invest, Cormorant Asset Management, BVF Partners, Janus Henderson Investors, Logos, Alta Partners, RA Capital, Boxer Capital, Cannaan | ||||
 | AllStripes | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $67.7M | Series B | 8/24/2021 | $50.3M | $308.52M | $9.62 | Lux Capital, Jazz Venture Partners, Spark Capital, Medidata Solution, McKesson Ventures, Maveron Capital, Arif Nathoo, Leila Zegna | ||||
 | Arthrosi Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $294.54M | Series E | 10/8/2025 | $148.1M | $385.03M | $6.54 | Prime Eight Capital, CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech | ||||
 | Ashvattha Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $123.69M | Series B | 1/13/2025 | $119M | $353.38M | $8.37 | Huadong Medicine, Natural Capital, Plum Alley, Tribe Capital | ||||
 | Atavistik | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260M | Series B-1 | 3/5/2026 | $40M | $422.55M | $1.20 | RA Capital Management | ||||
 | Atsena Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.9M | Series C-3 | 4/2/2025 | $60M | $337.46M | $4.13 | Bain Capital, Wellington Management, Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, Manning Family Foundation | ||||
 | Aura Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $225.08M | Series E | 3/22/2021 | $80.48M | $283.03M | $0.78 | Matrix Capital Management, Surveyor Capital, Rock Springs Capital, Adage Capital Management LP, Velosity Capital, Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital, Columbus Venture Partners | ||||